Abstract：
The increasing burden of type 2 diabetes (T2D), in relation to alarming rise in the prevalence; challenges in the diagnosis, prevention, and treatment; as well as the substantial impact of disease on longevity and quality of life, is a major concern in healthcare worldwide. Sulfonylureas (SUs) have been a cornerstone of T2D pharmacotherapy for over 60 years as oral antidiabetic drugs (OADs), while the newer generation SUs, such as gliclazide modified release (MR), are known to be associated with low risk of hypoglycemia in addition to the cardiovascular neutrality. This scoping review aimed to specifically address the current position of gliclazide MR among other SUs in the contemporary treatment paradigm for T2D and to provide a practical guidance document to assist clinicians in using gliclazide MR in real-life clinical practice. The main topics addressed in this paper include the role of early and sustained glycemic control and use of SUs in T2D management, the properties of gliclazide MR in relation to its effectiveness and safety, the use of gliclazide therapy in special populations, and the place of SUs as a class and gliclazide MR specifically in the current T2D treatment algorithm.
摘要：
2型糖尿病（T2D）负担的增加，与患病率惊人上升有关；诊断方面的挑战，预防,和治疗；以及疾病对寿命和生活质量的重大影响，是全球医疗保健的主要问题。作为口服抗糖尿病药物（OADs），60多年来一直是T2D药物治疗的基石，而新一代SU，如格列齐特调释（MR），除心血管中性外，已知与低血糖风险低有关。本范围审查旨在专门解决格列齐特MR在T2D的当代治疗范式中的其他SU中的当前位置，并提供实用的指导文件，以帮助临床医生在现实生活中使用格列齐特MR临床实践。本文讨论的主要主题包括早期和持续血糖控制的作用以及SUs在T2D管理中的使用，格列齐特MR与其有效性和安全性相关的特性，在特殊人群中使用格列齐特治疗，以及SU作为一类和格列齐特MR的位置，特别是在当前的T2D治疗算法中。
